ClinicalTrials.gg
CompletedNCT05008224KEYNOTE-C11Updated Jun 6, 2025Results posted

Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

A Phase 2 interventional study of Pembrolizumab and Doxorubicin in Classical Hodgkin Lymphoma, sponsored by Merck Sharp & Dohme LLC. Completed at 48 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
146
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) monotherapy, followed by chemotherapy, followed by pembrolizumab consolidation. The primary hypothesis of the study is that the complete response (CR) rate at the end of study intervention according to Lugano 2014 response criteria is higher than conventional chemotherapy.

02

Conditions studied

  • Classical Hodgkin Lymphoma

Keywords

  • Programmed Cell Death 1 (PD-1, PD1)
  • Programmed Cell Death-Ligand 1 (PD-L1, PDL1)
  • Programmed Cell Death-Ligand 2 (PD-L2, PDL2)
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include, but are not limited to the following:

  • Has a confirmed diagnosis of Ann Arbor Stage III or IV classical Hodgkin Lymphoma (cHL). Stage I and II participants may be enrolled, but must have at least one National Comprehensive Cancer Network (NCCN) unfavorable risk factor per protocol
  • Has measurable 2-fluorodeoxyglucose (FDG)-avid disease based on investigator assessment according to Lugano 2014 response criteria
  • Has not received prior radiation therapy, chemotherapy, immunotherapy, or other systemic therapy for the treatment of cHL before the first dose of study intervention
  • Has an (ECOG) Performance Status of 0 to 1 assessed within 7 days before the start of study intervention

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include, but are not limited to the following:

  • Has confirmed nodular lymphocyte-predominant Hodgkin Lymphoma (HL)
  • Has an uncontrolled intercurrent cardiovascular illness
  • Has received prior therapy with an anti-programmed cell death 1 protein (), anti-programmed cell death ligand 1 protein (PD-L1), or anti- programmed cell death ligand 2 protein (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor
  • Has received or is expected to receive a live or within 30 days before the first dose of study intervention
  • Is currently participating in or has participated in a study of an agent or has used an investigational device within 4 weeks before the first dose of study intervention
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy or any other form of therapy within 7 days prior the first dose of study medication
  • Has a known additional that is progressing or has required active treatment within the past 5 years
  • Has radiographically detectable central nervous system and/or carcinomatous meningitis
  • Has an active disease that has required systemic treatment in past 2 years
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has a history or current evidence of pulmonary fibrosis
  • Has had an allogenic tissue/solid organ transplant
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
146 participants (actual)

Study arms

  • Experimental
    Pembrolizumab Monotherapy + AVD Chemotherapy/escBEACOPP Chemotherapy + Pembrolizumab Consolidation

    After completing Positron Emission Tomography (PET) scan 1 during eligibility screening, participants received pembrolizumab monotherapy intravenous (IV) for three 3-week cycles followed by PET scan 2. Participants next received 2 phases of chemotherapy. In chemotherapy phase 1, all participants received doxorubicin in combination with vinblastine \& dacarbazine (AVD) IV for two 4-week cycles followed by PET scan 3. In chemotherapy phase 2, participants who were PET scan 3 negative, or positive and age ≥60 years, received up to 4 additional cycles of AVD IV, while participants who were PET scan 3 positive and age \<60 years received up to four 3-week cycles of escalated bleomycin in combination with etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, \& prednisone (escBEACOPP) IV. All participants then received pembrolizumab consolidation IV for four 6-week cycles followed by a final PET scan.

    Biological: Pembrolizumab · Drug: Doxorubicin · Drug: Vinblastine · Drug: Dacarbazine · Drug: Bleomycin · Drug: Etoposide · Drug: Cyclophosphamide · Drug: Vincristine · Drug: Procarbazine · Drug: Prednisone

Interventions

  • BiologicalPembrolizumab

    200 mg IV administered on Day 1 of each 3-week cycle for 3 cycles during pembrolizumab monotherapy. 400 mg IV administered on Day 1 of each 6-week cycle for 4 cycles as pembrolizumab consolidation.

    Also known as: MK-3475, SCH 900475, KEYTRUDA®

  • 25 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles in all participants after PET scan 2 and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age). 35 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive, \<60 years of age).

    Also known as: Adriamycin, DOXIL®, Rubex®

  • 6 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).

    Also known as: Alkaban-AQ®, Velban®

  • 375 mg/m\^2 IV administered as part of AVD chemotherapy on Days 1 and 15 of each 4-week cycle for 2 cycles after PET scan 2 (all participants) and up to 4 additional cycles after PET scan 3 (participants who are PET scan 3 negative, or positive and ≥60 years of age).

    Also known as: Dtic-Dome®

  • 10 units/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).

    Also known as: Blenoxane®

  • 200 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Days 1-3 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).

    Also known as: Toposar®, VePesid®, Etopophos®, VP-16, Etoposide phosphate

  • 1250 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 1 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).

    Also known as: Neosar®, Cytoxan®

  • 1.4 mg/m\^2 IV administered as part of escBEACOPP chemotherapy on Day 8 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).

    Also known as: Oncovin®, Vincasar PFS®

  • 100 mg/m\^2 orally (PO) administered as part of escBEACOPP chemotherapy on Days 1-7 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).

    Also known as: Matulane®

  • 40 mg/m\^2 PO administered as part of escBEACOPP chemotherapy on Days 1-14 of each 3-week cycle for up to 4 cycles after PET scan 3 (participants who are PET scan 3 positive and \<60 years of age).

    Also known as: Liquid Pred®, Meticorten®, Orasone®, Deltasone®

06

What researchers measure

Primary outcomes

  1. Complete Response (CR) Rate at the End of Study Intervention as Assessed by Blinded Independent Central Review (BICR) Per Lugano 2014 Response Criteria

    CR rate was assessed by BICR using Computed Tomography (CT) and PET scan according to Lugano 2014 response criteria (Cheson, B.D. et al, Journal of Clinical Oncology, 2014). At each timepoint, CR was determined by combining the anatomic response, metabolic response, and clinical data. The criteria for CR included complete metabolic (no/minimal 2-fluorodeoxyglucose \[FDG\] uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. Per protocol, participants who discontinued study intervention during pembrolizumab monotherapy, chemotherapy, or pembrolizumab consolidation, or are lost to follow-up, or receive any new non-study anticancer therapy prior to end of treatment were classified as non-responders. The percentage of participants who had CR after the completion of pembrolizumab consolidation is presented.

    Time frame: Up to approximately 24 months

Secondary outcomes

  1. CR Rate at the End of Study Intervention as Assessed by Investigator Per Lugano 2014 Response Criteria

    CR rate was assessed by the investigator using CT and PET scan according to Lugano 2014 response criteria (Cheson, B.D. et al, Journal of Clinical Oncology, 2014). At each timepoint, CR was determined by combining the anatomic response, metabolic response, and clinical data. The criteria for CR included complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. Per protocol, participants who discontinued study intervention during pembrolizumab monotherapy, chemotherapy, or pembrolizumab consolidation, or are lost to follow-up, or receive any new non-study anticancer therapy prior to end of treatment were classified as non-responders. The percentage of participants who had CR after the completion of pembrolizumab consolidation is presented.

    Time frame: Up to approximately 31 months

  2. Duration of Complete Response (DurCR) as Assessed by BICR Per Lugano 2014 Response Criteria

    DurCR was defined as the time from CR to progressive disease (PD) or death due to any cause, whichever came first. CR was assessed by BICR using CT and PET scan according to Lugano 2014 response criteria (Cheson, B.D. et al, Journal of Clinical Oncology, 2014). At each timepoint, CR was determined by combining the anatomic response, metabolic response, and clinical data. The criteria for CR included complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PD was defined as uptake moderately or markedly higher than the liver and/or new lesions. DurCR was analyzed by the Kaplan-Meier method for censored data and is presented for participants who demonstrated CR.

    Time frame: Up to approximately 31 months

  3. Rate of PET Negativity Assessed by BICR According to the FDG-PET 5-point Scale After Administration of Pembrolizumab Monotherapy (PET Scan 2)

    The rate of PET negativity was defined as the percentage of participants considered negative on the FDG-PET 5-point scale, as assessed by BICR according to Lugano 2014 response criteria (Cheson, B.D. et al, Journal of Clinical Oncology, 2014). Participants were assigned a single score on the FDG-PET 5-point scale measuring FDG uptake (1 = no uptake above background, 2 = uptake above background but ≤ mediastinum, 3 = uptake \> mediastinum but ≤ liver, 4 = uptake moderately \> liver, 5 = uptake markedly \> liver or new FDG-positive lesions). Higher scores corresponded to greater uptake (greater disease). FDG-PET 5-point scale scores of 1, 2, and 3 were considered negative and scores of 4 and 5 were considered positive. The percentage of participants who were assessed as negative at PET scan 2, after completion of 3 cycles of pembrolizumab monotherapy, is presented.

    Time frame: Up to approximately 10 weeks

  4. Rate of PET Negativity Assessed by BICR According to the FDG-PET 5-point Scale After Administration of Pembrolizumab Monotherapy and AVD Chemotherapy (PET Scan 3)

    The rate of PET negativity was defined as the percentage of participants considered negative on the FDG-PET 5-point scale, as assessed by BICR according to Lugano 2014 response criteria (Cheson, B.D. et al, Journal of Clinical Oncology, 2014). Participants were assigned a single score on the FDG-PET 5-point scale measuring FDG uptake (1 = no uptake above background, 2 = uptake above background but ≤ mediastinum, 3 = uptake \> mediastinum but ≤ liver, 4 = uptake moderately \> liver, 5 = uptake markedly \> liver or new FDG-positive lesions). Higher scores corresponded to greater uptake (greater disease). FDG-PET 5-point scale scores of 1, 2, and 3 were considered negative and scores of 4 and 5 were considered positive. The percentage of participants who were assessed as negative at PET scan 3, after completion of 3 cycles of pembrolizumab monotherapy and phase 1 AVD chemotherapy (2 AVD cycles), is presented.

    Time frame: Up to approximately 5 months

  5. Number of Participants Who Experienced an Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Per protocol, collection and reporting of AEs was based on the study treatment received by the participant (pembrolizumab, AVD chemotherapy, or escBEACOPP chemotherapy) at the time of the event. The number of participants who experienced an AE is reported.

    Time frame: Up to approximately 31 months

  6. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Per protocol, collection and reporting of AEs was based on the study treatment received by the participant (pembrolizumab, AVD chemotherapy, or escBEACOPP chemotherapy) at the time of the event. The number of participants who discontinued study intervention due to an AE is reported.

    Time frame: Up to approximately 17 months

07

Results

Posted Oct 16, 2024

Participant flow

Male or female participants with newly diagnosed early unfavorable or advanced-stage classical Hodgkin Lymphoma (cHL), who were at least 18 years old, were enrolled in this study.

Participant flow — Overall Study
MilestonePembrolizumab Monotherapy + AVD Chemotherapy/escBEACOPP Chemotherapy + Pembrolizumab Consolidation
Started146
Received ≥1 dose of pembrolizumab146
Received at ≥1 dose of avd chemotherapy136
Received at ≥1 dose of escbeacopp chemotherapy17
Completed0
Not completed146
Withdrew: Death3
Withdrew: Lost to follow-up2
Withdrew: Did not continue on extension study39
Withdrew: Transferred to extension study100
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryComplete Response (CR) Rate at the End of Study Intervention as Assessed by Blinded Independent Central Review (BICR) Per Lugano 2014 Response Criteria

CR rate was assessed by BICR using Computed Tomography (CT) and PET scan according to Lugano 2014 response criteria (Cheson, B.D. et al, Journal of Clinical Oncology, 2014). At each timepoint, CR was determined by combining the anatomic response, metabolic response, and clinical data. The criteria for CR included complete metabolic (no/minimal 2-fluorodeoxyglucose \[FDG\] uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. Per protocol, participants who discontinued study intervention during pembrolizumab monotherapy, chemotherapy, or pembrolizumab consolidation, or are lost to follow-up, or receive any new non-study anticancer therapy prior to end of treatment were classified as non-responders. The percentage of participants who had CR after the completion of pembrolizumab consolidation is presented.

Time frame:
Up to approximately 24 months
Reported as:
Number · Percentage of Participants
Complete Response (CR) Rate at the End of Study Intervention as Assessed by Blinded Independent Central Review (BICR) Per Lugano 2014 Response Criteria
Percentage of ParticipantsPembrolizumab Monotherapy + AVD Chemotherapy/escBEACOPP Chemotherapy + Pembrolizumab Consolidation
Complete Response (CR) Rate at the End of Study Intervention as Assessed by Blinded Independent Central Review (BICR) Per Lugano 2014 Response Criteria67.0 (58.9 to 74.7)
SecondaryCR Rate at the End of Study Intervention as Assessed by Investigator Per Lugano 2014 Response Criteria

CR rate was assessed by the investigator using CT and PET scan according to Lugano 2014 response criteria (Cheson, B.D. et al, Journal of Clinical Oncology, 2014). At each timepoint, CR was determined by combining the anatomic response, metabolic response, and clinical data. The criteria for CR included complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. Per protocol, participants who discontinued study intervention during pembrolizumab monotherapy, chemotherapy, or pembrolizumab consolidation, or are lost to follow-up, or receive any new non-study anticancer therapy prior to end of treatment were classified as non-responders. The percentage of participants who had CR after the completion of pembrolizumab consolidation is presented.

Time frame:
Up to approximately 31 months
Reported as:
Number · Percentage of Participants
CR Rate at the End of Study Intervention as Assessed by Investigator Per Lugano 2014 Response Criteria
Percentage of ParticipantsPembrolizumab Monotherapy + AVD Chemotherapy/escBEACOPP Chemotherapy + Pembrolizumab Consolidation
CR Rate at the End of Study Intervention as Assessed by Investigator Per Lugano 2014 Response Criteria71.9 (63.9 to 79.0)
SecondaryDuration of Complete Response (DurCR) as Assessed by BICR Per Lugano 2014 Response Criteria

DurCR was defined as the time from CR to progressive disease (PD) or death due to any cause, whichever came first. CR was assessed by BICR using CT and PET scan according to Lugano 2014 response criteria (Cheson, B.D. et al, Journal of Clinical Oncology, 2014). At each timepoint, CR was determined by combining the anatomic response, metabolic response, and clinical data. The criteria for CR included complete metabolic (no/minimal FDG uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PD was defined as uptake moderately or markedly higher than the liver and/or new lesions. DurCR was analyzed by the Kaplan-Meier method for censored data and is presented for participants who demonstrated CR.

Time frame:
Up to approximately 31 months
Reported as:
Median · Months
Duration of Complete Response (DurCR) as Assessed by BICR Per Lugano 2014 Response Criteria
MonthsPembrolizumab Monotherapy + AVD Chemotherapy/escBEACOPP Chemotherapy + Pembrolizumab Consolidation
Duration of Complete Response (DurCR) as Assessed by BICR Per Lugano 2014 Response CriteriaNA (NA to NA)
SecondaryRate of PET Negativity Assessed by BICR According to the FDG-PET 5-point Scale After Administration of Pembrolizumab Monotherapy (PET Scan 2)

The rate of PET negativity was defined as the percentage of participants considered negative on the FDG-PET 5-point scale, as assessed by BICR according to Lugano 2014 response criteria (Cheson, B.D. et al, Journal of Clinical Oncology, 2014). Participants were assigned a single score on the FDG-PET 5-point scale measuring FDG uptake (1 = no uptake above background, 2 = uptake above background but ≤ mediastinum, 3 = uptake \> mediastinum but ≤ liver, 4 = uptake moderately \> liver, 5 = uptake markedly \> liver or new FDG-positive lesions). Higher scores corresponded to greater uptake (greater disease). FDG-PET 5-point scale scores of 1, 2, and 3 were considered negative and scores of 4 and 5 were considered positive. The percentage of participants who were assessed as negative at PET scan 2, after completion of 3 cycles of pembrolizumab monotherapy, is presented.

Time frame:
Up to approximately 10 weeks
Reported as:
Number · Percentage of Participants
Rate of PET Negativity Assessed by BICR According to the FDG-PET 5-point Scale After Administration of Pembrolizumab Monotherapy (PET Scan 2)
Percentage of ParticipantsPembrolizumab Monotherapy
Rate of PET Negativity Assessed by BICR According to the FDG-PET 5-point Scale After Administration of Pembrolizumab Monotherapy (PET Scan 2)19.9
SecondaryRate of PET Negativity Assessed by BICR According to the FDG-PET 5-point Scale After Administration of Pembrolizumab Monotherapy and AVD Chemotherapy (PET Scan 3)

The rate of PET negativity was defined as the percentage of participants considered negative on the FDG-PET 5-point scale, as assessed by BICR according to Lugano 2014 response criteria (Cheson, B.D. et al, Journal of Clinical Oncology, 2014). Participants were assigned a single score on the FDG-PET 5-point scale measuring FDG uptake (1 = no uptake above background, 2 = uptake above background but ≤ mediastinum, 3 = uptake \> mediastinum but ≤ liver, 4 = uptake moderately \> liver, 5 = uptake markedly \> liver or new FDG-positive lesions). Higher scores corresponded to greater uptake (greater disease). FDG-PET 5-point scale scores of 1, 2, and 3 were considered negative and scores of 4 and 5 were considered positive. The percentage of participants who were assessed as negative at PET scan 3, after completion of 3 cycles of pembrolizumab monotherapy and phase 1 AVD chemotherapy (2 AVD cycles), is presented.

Time frame:
Up to approximately 5 months
Reported as:
Number · Percentage of Participants
Rate of PET Negativity Assessed by BICR According to the FDG-PET 5-point Scale After Administration of Pembrolizumab Monotherapy and AVD Chemotherapy (PET Scan 3)
Percentage of ParticipantsPembrolizumab Monotherapy + AVD Chemotherapy
Rate of PET Negativity Assessed by BICR According to the FDG-PET 5-point Scale After Administration of Pembrolizumab Monotherapy and AVD Chemotherapy (PET Scan 3)70.5
SecondaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Per protocol, collection and reporting of AEs was based on the study treatment received by the participant (pembrolizumab, AVD chemotherapy, or escBEACOPP chemotherapy) at the time of the event. The number of participants who experienced an AE is reported.

Time frame:
Up to approximately 31 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsPembrolizumab Monotherapy and ConsolidationAVD ChemotherapyescBEACOPP Chemotherapy
Number of Participants Who Experienced an Adverse Event (AE)13513217
SecondaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Per protocol, collection and reporting of AEs was based on the study treatment received by the participant (pembrolizumab, AVD chemotherapy, or escBEACOPP chemotherapy) at the time of the event. The number of participants who discontinued study intervention due to an AE is reported.

Time frame:
Up to approximately 17 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsPembrolizumab Monotherapy and ConsolidationAVD ChemotherapyescBEACOPP Chemotherapy
Number of Participants Who Discontinued Study Treatment Due to an AE1510

Adverse events

Collected over Up to approximately 31 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab Monotherapy and Consolidation0/146 (0%)26/146 (17.8%)122/146 (83.6%)
AVD Chemotherapy3/136 (2.2%)26/136 (19.1%)131/136 (96.3%)
escBEACOPP Chemotherapy0/17 (0%)6/17 (35.3%)17/17 (100%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventPembrolizumab Monotherapy and ConsolidationAVD ChemotherapyescBEACOPP Chemotherapy
Febrile neutropeniaBlood and lymphatic system disorders0/14612/1363/17
AnaemiaBlood and lymphatic system disorders0/1460/1361/17
NeutropeniaBlood and lymphatic system disorders0/1460/1361/17
ThrombocytopeniaBlood and lymphatic system disorders0/1460/1361/17
Myocardial infarctionCardiac disorders0/1460/1361/17
VomitingGastrointestinal disorders0/1460/1361/17
PyrexiaGeneral disorders6/1463/1361/17
AppendicitisInfections and infestations0/1461/1361/17
Pseudomonas infectionInfections and infestations0/1460/1361/17
UrosepsisInfections and infestations0/1461/1361/17
Most frequent other events
Showing 10 of 73
Most frequent other events
EventPembrolizumab Monotherapy and ConsolidationAVD ChemotherapyescBEACOPP Chemotherapy
Neutrophil count decreasedInvestigations11/14685/1367/17
AnaemiaBlood and lymphatic system disorders9/14619/1368/17
NauseaGastrointestinal disorders15/14654/1363/17
ThrombocytopeniaBlood and lymphatic system disorders0/1464/1366/17
Mucosal inflammationGeneral disorders2/1467/1366/17
White blood cell count decreasedInvestigations7/14624/1366/17
ConstipationGastrointestinal disorders5/14634/1361/17
FatigueGeneral disorders16/14620/1364/17
Lymphocyte count decreasedInvestigations4/14611/1364/17
HypokalaemiaMetabolism and nutrition disorders3/1461/1364/17

Baseline characteristics

The analysis population consisted of all participants who received at least 1 dose of pembrolizumab

Age, Continuous
Age, Continuous(Years)Pembrolizumab Monotherapy + AVD Chemotherapy/escBEACOPP Chemotherapy + Pembrolizumab Consolidation
Mean38.9 ± 16.3
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab Monotherapy + AVD Chemotherapy/escBEACOPP Chemotherapy + Pembrolizumab Consolidation
Female66
Male80
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab Monotherapy + AVD Chemotherapy/escBEACOPP Chemotherapy + Pembrolizumab Consolidation
Hispanic or Latino22
Not Hispanic or Latino108
Unknown or Not Reported16
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab Monotherapy + AVD Chemotherapy/escBEACOPP Chemotherapy + Pembrolizumab Consolidation
American Indian or Alaska Native3
Asian8
Native Hawaiian or Other Pacific Islander0
Black or African American0
White126
More than one race1
Unknown or Not Reported8
08

Study locations

48 sites
  • St Joseph Heritage Healthcare-Oncology ( Site 0004)
    Fullerton, California 92835, United States
  • Stanford Cancer Center ( Site 0023)
    Palo Alto, California 94304, United States
  • Northwestern Memorial Hospital ( Site 0002)
    Chicago, Illinois 60611, United States
  • OptumCare Cancer Care-Research Department ( Site 0005)
    Las Vegas, Nevada 89102, United States
  • University of Tennessee Medical Center-Cancer Institute ( Site 0006)
    Knoxville, Tennessee 37920, United States
  • Texas Oncology-Plano East ( Site 0020)
    Plano, Texas 75075, United States
  • Liverpool Hospital-Haematology ( Site 0906)
    Liverpool, New South Wales 2170, Australia
  • Mater Misericordiae Limited ( Site 0904)
    Brisbane, Queensland 4101, Australia
  • Princess Alexandra Hospital-Division of Cancer Services Trials Unit ( Site 0907)
    Woolloongabba, Queensland 4102, Australia
  • Monash Health-Haematology Research ( Site 0908)
    Clayton, Victoria 3168, Australia
  • Peter MacCallum Cancer Centre ( Site 0905)
    Melbourne, Victoria 3000, Australia
  • Cross Cancer Institute ( Site 0207)
    Edmonton, Alberta T6G 1Z2, Canada
  • Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0205)
    Greenfield Park, Quebec J4V 2H1, Canada
  • Jewish General Hospital ( Site 0200)
    Montreal, Quebec H3T 1E2, Canada
  • Hopital du Sacre-Coeur de Montreal ( Site 0206)
    Montreal, Quebec H4J 1C5, Canada
  • McGill University Health Centre ( Site 0209)
    Montréal, Quebec H4A 3J1, Canada
  • Centro Investigación del Cáncer James Lind ( Site 1200)
    Temuco, Araucania 4780000, Chile
  • Instituto Nacional del Cancer ( Site 1205)
    Chile, Region M. De Santiago 8380455, Chile
  • FALP-UIDO ( Site 1202)
    Santiago, Region M. De Santiago 6900941, Chile
  • Clínica Alemana de Santiago ( Site 1206)
    Santiago, Region M. De Santiago 8320325, Chile
  • Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 1204)
    Santiago, Region M. De Santiago 8330032, Chile
  • CHU Bordeaux Haut-Leveque ( Site 1505)
    Pessac, Aquitaine 33600, France
  • Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou-haematology ( Site 1502)
    Rennes, Bretagne 35033, France
  • Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 1504)
    Dijon, Cote-d Or 21000, France
  • centre hospitalier lyon sud-Service Hématologie ( Site 1501)
    Pierre-Bénite, Rhone 69310, France
  • Centre de Lutte Contre le Cancer - Centre Henri Becquerel Normandie Rouen-Service d'Hématologie ( Si
    Rouen, Seine-Maritime 76000, France
  • Rambam Health Care Campus ( Site 1907)
    Haifa, 3109601, Israel
  • Bnai Zion Medical Center-Hematology ( Site 1909)
    Haifa, 3339419, Israel
  • Hadassah Medical Center ( Site 1901)
    Jerusalem, 9112001, Israel
  • Sheba Medical Center-Hemato Oncology ( Site 1904)
    Ramat Gan, 5265601, Israel
  • ZIV Medical Center ( Site 1908)
    Safed, 1311001, Israel
  • Sourasky Medical Center ( Site 1905)
    Tel Aviv, 6423906, Israel
  • Azienda Ospedaliera Spedali Civili di Brescia-Hemathology ( Site 1801)
    Brescia, Lombardia 25123, Italy
  • ASST Grande Ospedale Metropolitano Niguarda ( Site 1803)
    Milan, Milano, Italy
  • Policlinico S. Orsola- Malpighi-Istituto di Ematologia L. e A. Seragnoli ( Site 1800)
    Bologna, 40138, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli-ISTITUTO DI EMATOLOGIA ( Site 1804)
    Roma, 00168, Italy
  • Klinika Hematologii - Instytut Hematologii i Transfuzjologii-Klinika Hematologii ( Site 0402)
    Warsaw, Mazowieckie 02-776, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
    Warszawa, Mazowieckie 02-781, Poland
  • Szpital Wojewódzki w Opolu-Hematology Department ( Site 0401)
    Opole, Opolskie 46-020, Poland
  • Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 0403)
    Gdańsk, Pomorskie 80-952, Poland
  • Moscow City Clinical Hospital S.P. Botkin ( Site 0702)
    Moscow, Moskva 125284, Russian Federation
  • First Pavlov State Medical University of Saint Petersburg-Raisa Gorbacheva Memorial Institut for Pe
    Saint Petersburg, Sankt-Peterburg 197022, Russian Federation
  • Almazov National Medical Research Centre ( Site 0704)
    Saint Petersburg, Sankt-Peterburg 197341, Russian Federation
  • Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 1031)
    L'Hospitalet Del Llobregat, Barcelona 08908, Spain
  • Hospital Universitario 12 de Octubre ( Site 1032)
    Madrid, 28041, Spain
  • Dokuz Eylül Üniversitesi ( Site 5002)
    Balçova, Izmir, Turkey
  • Ankara University Hospital Cebeci-hematology ( Site 5000)
    Ankara, 06100, Turkey
  • Vehbi Koc Vakfi - Amerikan Hastanesi ( Site 5001)
    Istanbul, 34365, Turkey
09

References and documents

Publications

  • Allen PB, Lu X, Chen Q, O'Shea K, Chmiel JS, Slonim LB, Sukhanova M, Savas H, Evens AM, Advani R, Pro B, Karmali R, Palmer B, Bayer RA, Eisner RM, Mou E, Dillehay G, Gordon LI, Winter JN. Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma. Blood Adv. 2023 Jun 27;7(12):2670-2676. doi: 10.1182/bloodadvances.2022008116. PubMed 36083129 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Oct 2023, 24 months.

Results were first posted in Oct 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2021
First posted
Aug 17, 2021
StartActual
Oct 7, 2021
Primary completionActual
Oct 11, 2023
CompletionActual
May 26, 2024
Results first posted
Oct 16, 2024
Last update
Jun 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05008224
Responsible party
Sponsor
First posted
Aug 17, 2021
Start date
Oct 7, 2021
Primary completion
Oct 11, 2023
Completion
May 26, 2024
Results posted
Oct 16, 2024
Last update
Jun 6, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion